AUS
NZ
UK
CA
USA
IND
Highlights
The Vaccine Group, a portfolio company of Frontier IP Group, begins animal testing for an ASF vaccine candidate.
The project is supported by The Pirbright Institute and the UK’s Biotechnology and Biological Sciences Research Council.
The vaccine employs a bovine herpesvirus vector compatible with DIVA diagnostics to monitor vaccinated livestock.
The animal vaccine sector forms a vital part of the broader biosciences and agricultural industries, which are integral to sustainable livestock production and food safety. This segment has gained increasing attention within indexes such as the FTSE 100 live due to the urgency of addressing viral outbreaks that disrupt food systems and international trade. One of the most persistent challenges in animal health is African Swine Fever (ASF), a disease that significantly impacts pig populations worldwide.
Development Progress by Frontier IP Group
Frontier IP Group PLC (LSE:FIPP), involved in the commercialisation of university intellectual property, recently reported a development from its portfolio company, The Vaccine Group. The group has initiated animal trials for its ASF vaccine candidate, a critical phase in the research and development timeline for solutions targeting viral livestock diseases. This marks a pivotal point in the company's efforts to contribute toward ASF control measures.
Collaboration with The Pirbright Institute
The ASF vaccine programme is being conducted in collaboration with The Pirbright Institute, which specialises in animal disease research. The initiative is funded by a Biotechnology and Biological Sciences Research Council award under its Industrial Partnership scheme. This partnership aligns expertise in veterinary virology with technological platforms aiming to improve animal health across agricultural sectors.
Vaccine Technology and Application
The ASF vaccine candidate is based on a bovine herpesvirus vector. This technology allows the incorporation of DIVA (Differentiating Infected from Vaccinated Animals) capability, which is essential for managing outbreaks through accurate surveillance. In controlled trials, pigs will receive the vaccine and subsequently be exposed to virulent ASF strains under laboratory conditions. The data collected during this phase will assist in understanding the candidate’s safety and ability to produce immune responses in swine populations.
Understanding African Swine Fever
ASF is a contagious viral disease affecting both wild and domestic pigs. Known for its high mortality rate, it creates significant challenges for food supply systems and has led to major losses in pig-producing countries. The absence of a validated vaccine contributes to widespread culling practices and trade disruptions. Containment measures are further complicated due to the resilience of the ASF virus in various environments and materials, prompting continued focus on vaccine research globally.
Global Biosecurity and Economic Context
Efforts to address ASF extend beyond animal health and encompass broader biosecurity strategies. Successful outcomes from animal trials may help to stabilise swine production and support the long-term viability of pig farming across various regions. These developments hold importance for maintaining global trade continuity and protecting agricultural economies. Progress in ASF control is being monitored by stakeholders in markets associated with the FTSE 100 live, where agricultural biotechnology remains a significant area of scientific investment.
Trial Phase Outlook
The continuation of animal trials represents a crucial step in evaluating the viability of ASF vaccines. The collaborative research by The Vaccine Group and The Pirbright Institute reflects a methodical approach to tackling complex animal diseases. Results from these trials will offer insight into the effectiveness of recombinant vaccine platforms in addressing biosecurity concerns linked to livestock pathogens.
